Jasper Therapeutics (JSPR) News Today $5.94 -0.08 (-1.25%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Analysts Set Expectations for JSPR FY2025 EarningsJanuary 23 at 2:11 AM | americanbankingnews.comAnalysts Offer Predictions for JSPR FY2025 EarningsJasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that theJanuary 22 at 6:49 AM | marketbeat.comShort Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1%Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,320,000 shares, a growth of 12.1% from the December 15th total of 2,070,000 shares. Approximately 20.6% of the shares of the company are sold short. Based on an average daily trading volume, of 412,100 shares, the short-interest ratio is presently 5.6 days.January 18, 2025 | marketbeat.comBrokers Issue Forecasts for JSPR Q1 EarningsJanuary 14, 2025 | americanbankingnews.comWhat is HC Wainwright's Forecast for JSPR Q1 Earnings?Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar forecasts that the companyJanuary 13, 2025 | marketbeat.comJasper Therapeutics price target lowered to $48 from $68 at RBC CapitalJanuary 10, 2025 | markets.businessinsider.comHC Wainwright Has Lowered Expectations for Jasper Therapeutics (NASDAQ:JSPR) Stock PriceHC Wainwright dropped their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday.January 10, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for JSPR FY2029 Earnings?Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar anticipates that the company wilJanuary 10, 2025 | marketbeat.comJasper Therapeutics (NASDAQ:JSPR) Given New $48.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada decreased their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday.January 9, 2025 | marketbeat.comStrong Therapeutic Potential and Financial Outlook for Jasper Therapeutics’ BriquilimabJanuary 9, 2025 | markets.businessinsider.comJasper Therapeutics price target lowered to $64 from $90 at BTIGJanuary 9, 2025 | markets.businessinsider.comJasper Therapeutics stock tumbles after study dataJanuary 8, 2025 | investing.comJasper Therapeutics reports data from BEACON study of briquilimabJanuary 8, 2025 | markets.businessinsider.comJasper data alleviates competitive concerns for Celldex, says CitiJanuary 8, 2025 | markets.businessinsider.comJasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous UrticariaJanuary 8, 2025 | globenewswire.comJasper Therapeutics (NASDAQ:JSPR) Receives "Market Outperform" Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday.January 6, 2025 | marketbeat.comJasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025January 6, 2025 | globenewswire.comJasper Therapeutics Positioned for Success in Urticaria Market with Upcoming Briquilimab DataJanuary 6, 2025 | markets.businessinsider.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has earned an average rating of "Buy" from the ten brokerages that are currently covering the company, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages thatJanuary 1, 2025 | marketbeat.comJasper Therapeutics' (JSPR) Outperform Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $68.00 target price on shares of Jasper Therapeutics in a research note on Monday.December 23, 2024 | marketbeat.comFranklin Resources Inc. Sells 118,900 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)Franklin Resources Inc. cut its holdings in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 17.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 579,636 shares of theDecember 22, 2024 | marketbeat.comWellington Management Group LLP Buys New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Wellington Management Group LLP purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,759 shares of the company's stock, valuedDecember 21, 2024 | marketbeat.comFmr LLC Acquires Shares of 38,361 Jasper Therapeutics, Inc. (NASDAQ:JSPR)Fmr LLC bought a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 38,361 shares of the company's stock, valued at approximately $722,000. Fmr LLC ownDecember 18, 2024 | marketbeat.comInsider Selling: Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells 900 Shares of StockDecember 13, 2024 | insidertrades.comVerition Fund Management LLC Makes New $477,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Verition Fund Management LLC acquired a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,353 shares of the company's stock,December 12, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Rating of "Buy" from AnalystsJasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has earned a consensus recommendation of "Buy" from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Ten analysts have rated the stock with a buy recommendation. The average twelve-month price target among brDecember 7, 2024 | marketbeat.comJasper Therapeutics initiated with an Outperform at BMO CapitalDecember 6, 2024 | markets.businessinsider.comBMO Capital Initiates Coverage of Jasper Therapeutics (JSPR) with Outperform RecommendationDecember 6, 2024 | msn.comBMO Capital Markets Initiates Coverage on Jasper Therapeutics (NASDAQ:JSPR)BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research note on Friday. They issued an "outperform" rating and a $63.00 target price for the company.December 6, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Samsara BioCapital LLCSamsara BioCapital LLC boosted its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 11.4% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 584,642 shares of the company's stock after acquiring an additional 59,642 shares during the quarDecember 5, 2024 | marketbeat.comJasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in AsthmaDecember 2, 2024 | globenewswire.comBraidwell LP Takes $9.09 Million Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)Braidwell LP purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 483,300 shares of the company's stock, valueNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Buys 180,852 Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR)Ally Bridge Group NY LLC lifted its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 82.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 399,466 shares of the company's stock after purchasing an additional 180,852 shareNovember 28, 2024 | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Holdings Lessened by Great Point Partners LLCGreat Point Partners LLC reduced its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 19.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 322,380 shares of the company's stock after selling 79,635 shares during the quarNovember 27, 2024 | marketbeat.comJasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And AsthmaNovember 18, 2024 | seekingalpha.comWe're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn RateNovember 17, 2024 | sg.finance.yahoo.comIs Jasper Therapeutics (JSPR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comJasper Therapeutics to Participate at Upcoming Investor ConferencesNovember 13, 2024 | globenewswire.comJasper Therapeutics (JSPR) Gets a Buy from RBC CapitalNovember 9, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)November 9, 2024 | markets.businessinsider.comAnalysts Bullish on Jasper Therapeutics as Briquilimab Trials Show PromiseNovember 8, 2024 | finance.yahoo.comPositive Expectations and Clinical Success Drive Buy Rating for Jasper TherapeuticsNovember 7, 2024 | markets.businessinsider.comPromising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in BriquilimabNovember 7, 2024 | markets.businessinsider.comJasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 7, 2024 | globenewswire.comOppenheimer Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)October 29, 2024 | markets.businessinsider.comJasper Therapeutics (NASDAQ:JSPR) Stock, Option ChainOctober 29, 2024 | benzinga.comHC Wainwright Reiterates Buy Rating for Jasper Therapeutics (NASDAQ:JSPR)HC Wainwright reaffirmed a "buy" rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday.October 24, 2024 | marketbeat.comJasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingOctober 24, 2024 | globenewswire.comBuy Rating on Jasper Therapeutics Driven by Promising Clinical Developments and Strategic AdvancementsOctober 24, 2024 | markets.businessinsider.comJasper Therapeutics commences open-label extension study of chronic urticariasOctober 23, 2024 | markets.businessinsider.com Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address JSPR Media Mentions By Week JSPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JSPR News Sentiment▼1.000.63▲Average Medical News Sentiment JSPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JSPR Articles This Week▼53▲JSPR Articles Average Week Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MBX Biosciences News Precigen News Olema Pharmaceuticals News Corvus Pharmaceuticals News Contineum Therapeutics News Chimerix News LifeVantage News enGene News Taysha Gene Therapies News biote News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JSPR) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
